An intravaginal drug delivery device comprising: a drug delivery device, and a therapeutically effective amount of a single active agent that is therapeutically effective for the treatment of endometriosis, wherein the drug delivery device delivers the single active agent directly to endometrial implants in women diagnosed with endometriosis, wherein the single active agent is selected from the group consisting of mifepristone and metabolites thereof.

Compounds, compositions, and methods for treating injuries caused by exposure to chemical warfare and similar agents are described herein.

Compounds, compositions, and methods for treating injuries caused by exposure to chemical warfare and similar agents are described herein.

Disclosed herein are emulsions comprising testosterone or related androgens, castor oil, cyclodextrin, Pemulen TR-2, Polyoxyl 40, and other ingredients. The compositions are useful for treating keratoconjunctivitis sicca and meibomian gland disease.

Disclosed herein are emulsions comprising testosterone or related androgens, castor oil, cyclodextrin, Pemulen TR-2, Polyoxyl 40, and other ingredients. The compositions are useful for treating keratoconjunctivitis sicca and meibomian gland disease.

Disclosed herein are emulsions comprising testosterone or related androgens, castor oil, cyclodextrin, Pemulen TR-2, Polyoxyl 40, and other ingredients. The compositions are useful for treating keratoconjunctivitis sicca and meibomian gland disease.

A pharmaceutical composition contains ACP (A-nor-5α androstane compound) as a first active ingredient and an anticancer drug as a second active ingredient. The composition has an antitumor function.

A pharmaceutical composition contains ACP (A-nor-5α androstane compound) as a first active ingredient and an anticancer drug as a second active ingredient. The composition has an antitumor function.

A solid matrix sustained release ophthalmic formulation for topical delivery of a solid ophthalmic drug to the eye, medical devices, drug cores, drug inserts and drug delivery systems comprising the formulation, methods of manufacturing the formulation, medical devices and their methods thereof for delivering the ophthalmic drug for a treatment period provided herein. The formulation disclosed herein is an admixture of an ophthalmic drug, and a combination of a hydrophobic polymer, a hydrophilic polymer and a surfactant, wherein the drug is eluted daily over an extended period of time at therapeutic dose of drug.

A solid matrix sustained release ophthalmic formulation for topical delivery of a solid ophthalmic drug to the eye, medical devices, drug cores, drug inserts and drug delivery systems comprising the formulation, methods of manufacturing the formulation, medical devices and their methods thereof for delivering the ophthalmic drug for a treatment period provided herein. The formulation disclosed herein is an admixture of an ophthalmic drug, and a combination of a hydrophobic polymer, a hydrophilic polymer and a surfactant, wherein the drug is eluted daily over an extended period of time at therapeutic dose of drug.